neu-1

NEU-1017 serves as a broad-spectrum antiparasitic compound, effectively inhibiting T. brucei, L. major, and P. falciparum with EC50 values of 210 nM, 240 nM, and 3 nM, respectively.

NEU-1045 is a T. brucei proliferation inhibitor, and is a promising lead with cross-pathogen activity. NEU-1045 inhibited T. brucei, T. cruzi, and L. major proliferation with good potency (T. brucei EC50 = 0.37 μM; T. cruzi EC50 = 2.8 μM; L. major EC50 =

NEU-1923 is a potent inhibitor of T. brucei proliferation (EC50= 0.37 μM).

NEU-1953 is a potential candidate for sleeping sickness.

Tyrphostin AG 879 (AG 879) effectively inhibits HER2 ErbB2 with an IC50 of 1 μM, demonstrating 100- and 500-fold higher selectivity for ErbB2 over EGFR and PDGFR, respectively.

TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2 neu, is utilized in the formulation of J-LEAPS vaccines [1].

TYVPANASL, a nine-amino-acid MHC I-binding epitope from HER2 neu for CD8 T cells, can be utilized in the development of J-LEAPS vaccines [1].

SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope, class II rat HER2 neu peptide designed for research on the class II HER2-DC1 vaccine [1].

SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2 neu peptide used in the investigation of class II HER2-DC1 vaccine studies [1].

IRGRILHDGAYSLTLQGLGIH TFA, a multi-epitope class II rat HER2 neu peptide, is utilized in the study of class II HER2-DC1 vaccines [1].

IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2 neu peptide used in HER2-DC1 vaccine research studies [1].

ELAAWCRWGFLLALLPPGIAG TFA (P5), a 21-amino-acid peptide (aa 5-25) originating from the rat HER2 neu protein, has been shown to elicit cytotoxic T lymphocyte (CTL) responses in mice with HER2-positive tumors [1].

ELAAWCRWGFLLALLPPGIAG (P5), a 21-amino acid peptide (aa 5-25) derivative of the rat HER2 neu protein, has been shown to elicit cytotoxic T lymphocyte (CTL) responses in mice with HER2-positive tumors [1].

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody that targets both HER2 neu and CD3. It functions by activating Fcγ type I III receptors, which facilitates the formation of a tri-cell complex involving tumor cells, T cells, and accessory cells. This compound has been utilized in the research of breast cancer [1].